Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study
| Autor: | Brian Werneburg, De Ren Huang, Javier Zambrano, Barry Hendin, Sheri Rosenblatt, Sibyl Wray, Robert T. Naismith |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
medicine.medical_specialty Activities of daily living Delphi Technique Polyethylene Glycols 03 medical and health sciences Multiple Sclerosis Relapsing-Remitting Naproxen 0302 clinical medicine Adjuvants Immunologic Injection site reaction Humans Medicine 030212 general & internal medicine Aged computer.programming_language business.industry Phase IIIb Trial Interferon-beta Middle Aged medicine.disease Treatment Outcome Physical therapy Drug Eruptions Neurology (clinical) Treatment decision making business computer 030217 neurology & neurosurgery Delphi Clinical psychology Patient education |
| Zdroj: | Neurodegenerative Disease Management. 7:39-47 |
| ISSN: | 1758-2032 1758-2024 |
| Popis: | Aim: The objective of this Delphi analysis was to obtain consensus on injection-site reaction (ISR) experience and mitigation strategies for patients with relapsing-remitting multiple sclerosis switching from nonpegylated interferons (IFNs) to peginterferon β-1a in the ALLOW Phase IIIb trial using a three-step approach. Methods: Study investigators and coordinators from investigative sites enrolling four or more patients in ALLOW participated in three rounds of questionnaires and interviews. Results: Respondents (n = 37) agreed that the most common ISR, erythema, was not disruptive to daily activities. Patient education, as a conversation with a clinician about ISR potential, was recommended. Conclusion: The consensus of Delphi respondents on ISR experience and ISR management after switching from nonpegylated IFNs to peginterferon β-1a can help inform treatment decisions and manage patient expectations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|